🇺🇸 FDA
Pipeline program

Fostamatinib

Pro00113327

Phase 1 small_molecule active

Quick answer

Fostamatinib for Chronic Graft Versus Host Disease is a Phase 1 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
RIGEL PHARMACEUTICALS INC
Indication
Chronic Graft Versus Host Disease
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials